FDA Clears First High-Field MRI System Designed Specifically for Newborns
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Eyas Medical Imaging’s Ascent³ᵀ neonatal magnetic resonance imaging (MRI) system, a groundbreaking device engineered to address the unique anatomical needs of newborns and infants. This marks a significant advancement in pediatric medical imaging, promising more detailed and accessible diagnostics for some of the most vulnerable patients.
The Ascent³ᵀ is distinguished as the first high-field, three Tesla (3T) MRI system dedicated exclusively to neonatal and infant imaging. This higher field strength allows for comprehensive and detailed scans of critical organs, including the heart, lungs, abdomen, and brain, offering clinicians unprecedented clarity in diagnosis.
Traditionally, utilizing adult-size MRI systems for neonates has presented considerable challenges. The new system directly addresses these limitations, providing improved imaging and diagnostic capabilities tailored to the specific needs of this patient population. According to a company release, a major hurdle in neonatal MRI has been the logistical difficulty and risk associated with transporting fragile newborns from the neonatal intensive care unit (NICU) to often distant MRI suites within hospitals.
Eyas Medical Imaging’s innovative design overcomes this obstacle with a compact, whole-body 3T neonatal MRI system capable of being installed directly within the NICU. This proximity minimizes transport time and potential complications for these delicate patients. Furthermore, the system operates virtually helium-free, eliminating the need for a traditional quench pipe or external venting infrastructure, simplifying installation and reducing operational costs.
The development of the Ascent³ᵀ was informed by extensive experience gained at Cincinnati Children’s Hospital, where over 1,700 infant MRI scans were successfully performed using prototype systems. Key features include a detachable patient table that also functions as a transport device, enhancing workflow efficiency within the NICU environment. The technology also seamlessly integrates operating software, advanced electronics, and pulse sequences from Philips Medical Systems Nederland.
“510(k) clearance marks a significant milestone for the company and reflects our mission to enable healthcare professionals to save more babies’ lives with state-of-the-art, precision imaging,” stated Matt Storer, president and CEO of Eyas Medical Imaging.
Eyas Medical Imaging is currently focused on scaling up operations in preparation for the commercial launch of Ascent³ᵀ in the United States later this year. As of now, the device has not yet been approved for commercial distribution in other countries.
